These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31318208)

  • 21. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
    Du SS; Fang YQ; Zhang W; Rao GW
    Curr Med Chem; 2024; 31(20):2900-2920. PubMed ID: 38904160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis.
    Kircik L; Aldredge LM; DiRuggiero D
    J Drugs Dermatol; 2024 Aug; 23(8):645-652. PubMed ID: 39093663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.
    Leit S; Greenwood J; Carriero S; Mondal S; Abel R; Ashwell M; Blanchette H; Boyles NA; Cartwright M; Collis A; Feng S; Ghanakota P; Harriman GC; Hosagrahara V; Kaila N; Kapeller R; Rafi SB; Romero DL; Tarantino PM; Timaniya J; Toms AV; Wester RT; Westlin W; Srivastava B; Miao W; Tummino P; McElwee JJ; Edmondson SD; Masse CE
    J Med Chem; 2023 Aug; 66(15):10473-10496. PubMed ID: 37427891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
    Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
    Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
    Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
    Tran NV; Nguyen LTA; Lim KW; Phan AT
    Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multiple-action allosteric inhibition of TYK2 by deucravacitinib: Insights from computational simulations.
    Bao Y; Xu R; Guo J
    Comput Biol Chem; 2024 Dec; 113():108224. PubMed ID: 39353258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
    Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
    Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
    Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
    Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
    Muromoto R; Shimoda K; Oritani K; Matsuda T
    Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.
    Menet CJ
    Pharm Pat Anal; 2014 Jul; 3(4):449-66. PubMed ID: 25291316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of imidazo[1,2-
    Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
    Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
    Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M
    J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
    Norman P
    Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.